tiprankstipranks
Advertisement
Advertisement
Tango Therapeutics price target raised to $69 from $55 at Leerink
PremiumThe FlyTango Therapeutics price target raised to $69 from $55 at Leerink
3d ago
Catanzaro Raises TNGX Price Target to $36, Reiterates Buy on Promising Vopimetostat/Daraxonrasib Data in Pancreatic Cancer
Premium
Ratings
Catanzaro Raises TNGX Price Target to $36, Reiterates Buy on Promising Vopimetostat/Daraxonrasib Data in Pancreatic Cancer
3d ago
Tango Therapeutics price target raised to $36 from $30 at Mizuho
Premium
The Fly
Tango Therapeutics price target raised to $36 from $30 at Mizuho
3d ago
Tango Therapeutics price target raised to $35 from $21 at B. Riley
PremiumThe FlyTango Therapeutics price target raised to $35 from $21 at B. Riley
3d ago
Tango Therapeutics rises 32.1%
Premium
The Fly
Tango Therapeutics rises 32.1%
3d ago
RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position
Premium
The Fly
RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position
3d ago
Tango Therapeutics falls -14.9%
PremiumThe FlyTango Therapeutics falls -14.9%
27d ago
Tango Therapeutics price target raised to $30 from $20 at Mizuho
Premium
The Fly
Tango Therapeutics price target raised to $30 from $20 at Mizuho
27d ago
Tango Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
Tango Therapeutics downgraded to Neutral from Overweight at Piper Sandler
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100